Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters. ...
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will...
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk's Wegovy and Zepbound from Eli Lilly. Amgen has an experimental dual mechanism obesity drug in mid-stage trials it hopes will have fewer side effects with less frequent dosing than Wegovy or Zepbound, Chief Scientific Officer Jay Bradner told Reuters at the annual JPMorgan health conference in San Francisco this week.
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk's...
Germany's Bayer will continue its expansion into the U.S. despite its November announcement that its promising blood thinner candidate failed to demonstrate superiority over a competing medicine, the drugmaker's pharmaceuticals head Stefan Oelrich said on Monday. Bayer's experimental anticoagulant asundexian could still be a blockbuster if its second trial for stroke prevention reads out positively, Oelrich told Reuters at the JPMorgan health conference in San Francisco. He said there is also strong opportunity in the U.S. for the company's cardiovascular and menopause sy...